These findings suggest that patients with NPC and increased levels of plasma EBV DNA may be an enriched group of patients with NPC at the highest risk of recurrence; this may be a population to select for additional adjuvant treatment after definitive chemoradiation, such as VEGF inhibition or PD1 or PDL1 inhibition. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.